|
| Comparative analysis of antibody responses to SARS-CoV-2 in various populations |
| Received:January 20, 2021 Revised:April 20, 2021 |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/BG.2021012021102 |
| KeyWord:SARS-CoV-2 serological assay nucleocapsid protein receptor-binding domain spike protein neutralizing antibody |
| Author | Institution |
| Lei Liu |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China |
| Wanbing Liu |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China |
| Yan Liu |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China |
| Guomei Kou |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China |
| Yaqiong Zheng |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China |
| Liping Cai |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China |
| Shengdian Wang |
CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China |
| Shangen Zheng |
Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China |
|
| Hits: 865 |
| Download times: 1753 |
| Abstract: |
| This paper aimed to analyze antibody responses to SARS-CoV-2 in various populations. Two hundred and six COVID-19 patients, 46 convalescent patients, and 270 healthy population were enrolled. Antibodies against nucleocapsid protein (N) and spike protein's receptor-binding domain (RBD), and neutralizing antibody were detected. The results demonstrated both anti-N and anti-RBD antibodies could be detected in about 80% of COVID-19 patients and 90% of convalescent patients, while no antibodies could be detected in some convalescents and patients even after 14 days post-onset of symptoms. The level of anti-RBD antibody strongly correlated with the neutralizing activity of sera from these two cohorts. The titer of neutralizing antibody was lower in convalescents than that in active COVID-19 patients. In addition, the titer of neutralizing antibody was less than 1:80 in none of the severe COVID-19 patients, 18.8% in non-severe COVID-19 patients, and 32.6% in convalescents. The study suggests that the level of anti-RBD antibody is closely related to neutralization activity in COVID-19 patients and convalescents. Some SARS-CoV-2-infected cases trigger a weak antiviral immune response, and the level of neutralizing antibody may have a faster decay rate. |
| Close |
|
|
|
